Lonza - Custom Pharmaceutical and Biotechnological Manufacturing Solutions

For nearly 30 years Lonza has been offering the life sciences industry world-class, customer-focused contract manufacturing and development services for active pharmaceutical ingredients, biologics and functional foods. Today customers include the leading pharmaceutical, biotechnology, bioresearch, nutrition and personal care businesses, along with hundreds of start-up, emerging and mid-size companies from around the world.

The active ingredients we make are ultimately used by our customers in innovative medicines - treating patients with cardiovascular diseases, cancer, neurological and infectious diseases - as well as in food, feed, cosmetics, and industrial applications.

Pharmaceutical contract manufacturing and development

As a premier contract manufacturing and development company, Lonza employs a broad yet flexible tool box of capabilities and technologies to help innovative companies strengthen their pipelines, increase product quality, improve production processes, navigate the development and regulatory process, lower their cost of goods, get to market faster and focus on their core competencies.

We leverage five core manufacturing platforms – advanced chemical synthesis, peptides synthesis, microbial fermentation, mammalian cell culture and cell therapy – with production facilities on three continents. With these capabilities, we are uniquely able to offer our clients synergies between chemical synthesis and biotechnology to enable the production of tailor-made intermediates and APIs for use as pharmaceuticals, biotherapeutics, nutraceuticals, cosmeceuticals and animal health products.

Chemical and peptide production

Our Chemical Manufacturing business is a leader in the cGMP production and development of complex pharmaceutical ingredients, peptides, advanced chemical intermediates and starting materials. Using the industry's most advanced process know-how, strategic global sourcing, essential infrastructure and backward integration, we provide best-in-class manufacturing and lifecycle management services.

From solid-phase synthesis and microreactors to highly potent active pharmaceutical ingredients and antibody drug conjugates, Lonza's track record, capabilities and experience in chemical and peptide production are unparalleled. We offer secure supply from four sites: Visp, Switzerland; Nansha, China; Riverside, Pennsylvania (US); and Braine, Belgium.

Lead optimisation and early-stage development services

The Development Services & Biologics R&D business provides lead optimisation and early-stage development services to help customers build stronger biopharmaceutical pipelines and improve individual drug candidates. Using advanced technologies such as the AggreSolve™ protein aggregation predictor, the Epibase® immunogenicity prediction platform, and the Tripole® protein engineering platform, the services group is able to identify drug efficacy or manufacturing challenges early on, which provides the opportunity to address them and create safer and more cost-effective biotherapies for our customers.

We offer fast-track, high-quality cell line constructions, strain design, a range of analytical, purification, technology and process development services, and full regulatory support. These services aim to leave the customer with a more robust, viable and cost-effective biologic. Services are carried out in Slough, UK; Singapore; Visp, Switzerland; and Hopkinton, Massachusetts (US); and Walkersville, Maryland (US).

Small-scale to large-scale bioproduction services

Using mammalian cell culture, microbial fermentation, and cell therapy, the Biological Manufacturing business offers small- to large-scale bioproduction capabilities to biotechnology and biopharmaceutical companies worldwide. Working hand-in-hand with the Development Services & Biologics R&D business, we are able to efficiently manufacture therapeutic monoclonal antibodies, recombinant proteins, antibody fragments, vaccines and plasmid DNA using industry-leading technologies such as the GS Gene Expression System™ and XS Microbial Expression Technologies™.

From technology transfer and scale-up to full-scale manufacturing and purification, Lonza's highly qualified scientists and extensive know-how can turn a promising laboratory discovery into a viable marketed product. Production sites include Slough, UK; Portsmouth, NH (US); Singapore; Porrino, Spain; Hopkinton, Massachusetts (US); Visp, Switzerland; Walkersville, Maryland (US); and Verviers, Belgium.

Complementary pharmaceutical development services

With the support of the Lonza's two other divisions, we are able to offer a wide range of complementary products and services, such as non-GMP chemical manufacturing, custom and bulk media, bioprocess containers, laboratory equipment, and preclinical analytical services to our customers.

From lead optimisation and early development through launch to commercial leadership and mature market supply, Lonza's complete range of development services, industry-leading manufacturing processes, broad technology platform and lifecycle management experience can help customers take their products to the next level of success – be it a critical milestone, technical advancement, regulatory phase, new market entry, commercial leadership or off-patent protection.

Core technologies and expertise

Lonza's core technologies are:

• Microbial fermentation
• Advanced chemical synthesis (APIs and HPAPIs)
• Antibody drug conjugates (ADCs)
• Peptide synthesis
• Mammalian cell culture
• Cell therapy
• Viral-based therapeutics

We have cutting-edge product expertise in the following fields:

• Active and functional ingredients
• Advanced intermediates
• Highly potent APIs (HPAPIs)
• Highly active pharmaceutical ingredients (HAPIs)
• Biocatalysis
• Biotransformations
• Antibody drug conjugates (ADCs)
• Peptides
• Vaccines
• Plasmid DNA
• Recombinant novel proteins
• Fragmented antibodies (Fabs)
• Monoclonal antibodies (mAbs)
• Cell therapy
• Viral-based therapeutics